GlassScriptPhysician profile
James M Otto
NPI 1477690766
$3,077.99
in general payments reported to CMS, 2019-2025
24 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $152 · 2021: $45.02 · 2022: $1,840 · 2023: $303 · 2024: $107 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $1,368.22 | 2022 | |
| Novo Nordisk INC | $620.59 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $342.28 | 2020-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.80 | 2020-2025 | Ofev, Jardiance |
| Amgen INC. | $89.59 | 2019-2023 | Repatha, Otezla |
| Astellas Pharma US INC | $74.43 | 2019-2020 | |
| Pfizer INC. | $53.63 | 2019-2025 | |
| Abbvie INC. | $51.96 | 2022-2025 | |
| Dexcom, INC. | $41.75 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $38.30 | 2023-2024 | Arexvy, Shingrix |
| Lilly USA, LLC | $34.74 | 2022-2023 | Mounjaro |
| Exact Sciences Corporation | $33.07 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $30.85 | 2019-2021 | |
| Mylan Specialty L.P. | $29.94 | 2022 | |
| Allergan, INC. | $28.13 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27.88 | 2019-2021 | |
| Abbott Laboratories | $18.65 | 2023 | Confirm Rx |
| Janssen Pharmaceuticals, INC | $16.11 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.64 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.46 | 2019 | |
| Esperion Therapeutics, INC. | $13.50 | 2022 | |
| Sanofi Pasteur INC. | $12.73 | 2019 | |
| Horizon Therapeutics Plc | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Otto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.